CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
个体化医学时代肿瘤学中改变实践的治疗综述
英文原题：A Review of Practice-Changing Therapies in Oncology in the Era of Personalized Medicine.
查看英文原题
A Review of Practice-Changing Therapies in Oncology in the Era of Personalized Medicine.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
过去十年，人们深入认识了促进肿瘤发生和治疗耐药的宿主及肿瘤因素组成。这些认识推动了多类新药的创新设计，并使其成为癌症治疗新的标准方案，包括新型抗体药物偶联物、CAR-T 细胞疗法和双特异性 T 细胞衔接器（BiTE）。某些宿主因素，例如微生物组组成，不仅逐渐成为预测抗癌治疗应答和毒性的生物标志物，也可能成为调节抗肿瘤应答的有用工具。癌症治疗正逐渐从“一刀切”模式转向根据宿主和肿瘤特征定制的个体化治疗。本评论介绍这些新兴疗法的基本概念及其抗癌承诺和挑战。
展开英文摘要原文
In the past decade, a lot of insight was gathered into the composition of the host and tumor factors that promote oncogenesis and treatment resistance. This in turn has led to the ingenious design of multiple new classes of drugs, which have now become the new standards of care in cancer therapy. These include novel antibody-drug conjugates, chimeric antigen receptor T cell therapies (CAR-T), and bispecific T cell engagers (BitTE).
Certain host factors, such as the microbiome composition, are also emerging not only as biomarkers for the response and toxicity to anti-cancer therapies but also as potentially useful tools to modulate anti-tumor responses. The field is slowly moving away from one-size-fits-all treatment options to personalized treatments tailored to the host and tumor. This commentary aims to cover the basic concepts associated with these emerging therapies and the promises and challenges to fight cancer.
论文信息
- 作者
- Capella MP、Esfahani K
- 单位
- Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital, Departments of Medicine and Oncology, McGill University, Montreal, QC H3T 1E9, Canada.Canada
- 文献类型
- 综述
- 期刊
- Current oncology (Toronto, Ont.)2024 Apr 2
- 原文标识
- PubMed 38668046 · DOI 10.3390/curroncol31040143
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →